Department of Environmental Toxicology, The Institute of Environmental and Human Health (TIEHH), Texas Tech University, Lubbock, TX 79416, United States.
Department of Dermatology, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 216, 1550 Orleans Street, Baltimore, MD 21231, United States.
Curr Top Med Chem. 2019;19(23):2098-2113. doi: 10.2174/1568026619666190902151307.
Over the past decades, designing therapeutic strategies to target KRAS-mutant cancers, which is one of the most frequent mutant oncogenes among all cancer types, have proven unsuccessful regardless of many concerted attempts. There are key challenges for KRAS-mutant anticancer therapy, as the complex cellular processes involved in KRAS signaling has present. Herein, we highlight the emerging therapeutic approaches for inhibiting KRAS signaling and blocking KRAS functions, in hope to serve as a more effective guideline for future development of therapeutics.
在过去的几十年中，设计针对 KRAS 突变型癌症的治疗策略一直未能成功，KRAS 突变是所有癌症类型中最常见的突变致癌基因之一，尽管进行了许多协同尝试。由于涉及 KRAS 信号的复杂细胞过程，KRAS 突变型抗癌治疗存在关键挑战。在此，我们重点介绍了抑制 KRAS 信号和阻断 KRAS 功能的新兴治疗方法，希望为未来治疗药物的开发提供更有效的指导。
